glp-1analogs
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| glp-1analogs [2026/11/03 23:35] – [semaglutide] gary1 | glp-1analogs [2026/11/03 23:36] (current) – [semaglutide] gary1 | ||
|---|---|---|---|
| Line 66: | Line 66: | ||
| *in Jan 2024, TGA approved the registration of a **Wegovy injectable** for those aged over 12 yrs with obesity and body weight above 60kg(([[https:// | *in Jan 2024, TGA approved the registration of a **Wegovy injectable** for those aged over 12 yrs with obesity and body weight above 60kg(([[https:// | ||
| *in Nov 2026, TGA approved the registration of a **Wegovy oral tablet** in 1.5mg, 4mg, 9mg and 25mg strengths but only for adults with clinical obesity | *in Nov 2026, TGA approved the registration of a **Wegovy oral tablet** in 1.5mg, 4mg, 9mg and 25mg strengths but only for adults with clinical obesity | ||
| - | ***weekly s/c injections** as it has a long half life of ~ 1 week due to binding to albumin | + | ***weekly s/c injections** |
| * start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycaemic control is needed, increase to 1 mg once weekly | * start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycaemic control is needed, increase to 1 mg once weekly | ||
| *in Australia, it is covered by PBS on an authority prescription for some diabetic patients only(([[https:// | *in Australia, it is covered by PBS on an authority prescription for some diabetic patients only(([[https:// | ||
glp-1analogs.txt · Last modified: by gary1